Kiniksa Pharmaceuticals International (KNSA) Q3 2024 earnings summary

Executive summary

• ARCALYST net product revenue reached $112.2 million in Q3 2024, up 73% year-over-year, with over 2,550 prescribers and strong commercial execution.

• Full-year 2024 ARCALYST net sales guidance raised to $410–$420 million, reflecting continued momentum and ~78% year-over-year growth at midpoint.

• Abiprubart Phase 2b trial for Sjögren's Disease is enrolling, with clinical development fully funded and broad autoimmune potential.

• Net loss for Q3 2024 was $12.7 million, an improvement from $13.9 million in Q3 2023; accumulated deficit reached $512.3 million.

• Completed redomiciliation from Bermuda to the United Kingdom in June 2024.

Financial highlights

• Q3 2024 product revenue was $112.2 million, up from $64.8 million in Q3 2023; nine-month product revenue was $294.5 million, up from $162.0 million year-over-year.

• Total operating expenses for Q3 2024 were $121.9 million, up from $78.0 million in Q3 2023, including $29.3 million in collaboration expenses.

• Net loss for Q3 2024 was $12.7 million; net loss per share was $(0.18).

• Cash, cash equivalents, and short-term investments totaled $223.8 million as of September 30, 2024, with no debt.

• Cost of goods sold rose to $20.1 million in Q3 2024, mainly due to higher sales and technology transfer costs.

Outlook and guidance

• 2024 ARCALYST net product revenue guidance increased to $410–$420 million, up from prior $405–$415 million.

• Company expects to remain cash flow positive on an annual basis, with cash reserves funding the current operating plan.

• Cash, cash equivalents, and short-term investments expected to fund operations and capital expenditures for at least the next 12 months.